TD Cowen analyst Ritu Baral has maintained their bullish stance on BNTC stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ritu Baral has given his Buy rating due to a combination of factors surrounding Benitec Biopharma’s financial and clinical progress. The company has a strong cash position of $98 million, which is projected to sustain operations through 2027. This financial stability supports the ongoing Phase 1b/2a trial and the anticipated start of a registrational trial in the second half of 2026.
Additionally, the company’s investigational therapy, BB-301, is advancing in its clinical trials for OPMD dysphagia, with promising interim data expected in the fourth quarter of 2025. The study involves both objective and subjective measures, which will provide comprehensive insights into the therapy’s efficacy. These factors, combined with strategic financial management and promising clinical data, underpin the Buy rating recommendation.
In another report released today, Citizens JMP also reiterated a Buy rating on the stock with a $20.00 price target.